North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country

  • Product Code:
    RP-ID-10346703
  • Published Date:
    5 Jan 2021
  • Region:
    Global
  • Pages:
    131
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-26

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

North America pharmaceutical CDMO market is expected to grow by 6.0% annually in the forecast period and reach $101.1 billion by 2030 driven by increasing demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.
Highlighted with 37 tables and 50 figures, this 131-page report “North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” is based on a comprehensive research of the entire North America pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country.

Based on Category, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical Industry
• Biopharmaceutical Industry

Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Pharmaceutical Contract Manufacturing Organization (CMO)
• Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
• Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
• Secondary Packaging
Pharmaceutical Contract Research Organization (CRO)
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services

Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications

Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America pharmaceutical CDMO market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK North America Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 23
2.2 Major Growth Drivers 25
2.3 Market Restraints and Challenges 30
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of North America Market by Category 41
3.1 Market Overview by Category 41
3.2 Pharmaceutical Industry 43
3.3 Biopharmaceutical Industry 44
4 Segmentation of North America Market by Service Type 45
4.1 Market Overview by Service Type 45
4.2 Pharmaceutical Contract Manufacturing Organization (CMO) 47
4.2.1 Active Pharmaceutical Ingredients (API) 48
4.2.2 Finished Dosage Formulations (FDF) 49
4.2.3 Secondary Packaging 51
4.3 Pharmaceutical Contract Research Organization (CRO) 52
4.3.1 CRO for Pre-clinical Development 54
4.3.2 CRO for Phase I Trials 55
4.3.3 CRO for Phase II Trials 56
4.3.4 CRO for Phase III Trials 57
4.3.5 CRO for Phase IV Trials 58
4.3.6 Laboratory Services 59
4.3.7 Consulting Services 60
4.3.8 Data Management Services 61
5 Segmentation of North America Market by Therapeutic Application 62
5.1 Market Overview by Therapeutic Application 62
5.2 Infectious Diseases 64
5.3 Oncology 65
5.4 Metabolic Disorders 66
5.5 Cardiovascular Disorders 67
5.6 Central Nervous System 68
5.7 Pulmonary Disorders 69
5.8 Gastrointestinal Disorders 70
5.9 Other Therapeutic Applications 71
6 Segmentation of North America Market by End User 72
6.1 Market Overview by End User 72
6.2 Pharmaceutical & Biopharmaceutical Companies 74
6.3 Medical Device Companies 75
6.4 Academic Institutes 76
7 North America Market 2019-2030 by Country 77
7.1 Overview of North America Market 77
7.2 U.S. 80
7.3 Canada 84
7.4 Mexico 86
8 Competitive Landscape 88
8.1 Overview of Key Vendors 88
8.2 New Product Launch, Partnership, Investment, and M&A 92
8.3 Company Profiles 93
8.3.1 Company Profiles of CMO 93
Aenova Group 93
Baxter BioPharma Solutions 96
Boehringer Ingelheim 97
Catalent Inc. 98
Famar S.A. 99
Hospira, Inc. 100
Jubilant Life Sciences Ltd. 101
Lonza Group 102
Patheon Inc. 103
Pfizer CentreSource 104
Recipharm AB 105
Vetter Pharma International GmbH 106
8.3.2 Company Profiles of CRO 108
Charles River Laboratories 108
CMIC Co. Ltd 110
Covance Inc. 111
Hangzhou Tigermed Consulting Co Ltd 112
ICON Plc 113
IQVIA Holdings Inc. 114
LSK North America Pharma Service Co Ltd 115
Novotech Pty Ltd 116
PAREXEL International Corporation 117
Pharmaceutical Product Development LLC (PPD) 118
PRA Health Sciences Inc. 119
Quanticate Ltd 120
Samsung Bioepis Co. Ltd 121
SGS SA (SGS Life Sciences) 122
Syneos Health Inc. 123
WuXi AppTec Inc. 124
9 Investing in North America Market: Risk Assessment and Management 125
9.1 Risk Evaluation of North America Market 125
9.2 Critical Success Factors (CSFs) 128
Related Reports and Products 131Table 1. Snapshot of North America Pharmaceutical CDMO Market in Balanced Perspective, 2019-2030 18
Table 2. Growth Rate of World Real GDP, 2017-2021 21
Table 3. World Top 10 Pharmaceutical Companies Based on Projected R&D Spending in 2026, $ bn 27
Table 4. Worldwide Total Number of Registered Clinical Trials 29
Table 5. Main Product Trends and Market Opportunities in North America Pharmaceutical CDMO Market 33
Table 6. North America Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 41
Table 7. North America Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 45
Table 8. North America Pharmaceutical CDMO Market: CMO by Product, 2019-2030, $ bn 47
Table 9. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn 48
Table 10. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn 50
Table 11. North America Pharmaceutical CDMO Market: CRO by Service, 2019-2030, $ bn 53
Table 12. North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 62
Table 13. North America Pharmaceutical CDMO Market by End User, 2019-2030, $ bn 72
Table 14. North America Pharmaceutical CDMO Market by Country, 2019-2030, $ bn 78
Table 15. U.S. Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 82
Table 16. U.S. Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 82
Table 17. U.S. Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 82
Table 18. Canada Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 85
Table 19. Canada Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 85
Table 20. Canada Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 85
Table 21. Mexico Pharmaceutical CDMO Market by Category, 2019-2030, $ bn 87
Table 22. Mexico Pharmaceutical CDMO Market by Service Type, 2019-2030, $ bn 87
Table 23. Mexico Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, $ bn 87
Table 24. Breakdown of North America CMO Market by Key Vendor, 2019, % 90
Table 25. Breakdown of North America CRO Market by Key Vendor, 2019, % 90
Table 26. Aenova Group: Company Snapshot 93
Table 27. Aenova Group: Business Segmentation 93
Table 28. Aenova Group: Product Portfolio 95
Table 29. Aenova Group: Revenue, 2016-2018, $ bn 95
Table 30. Aenova Group: Recent Developments 95
Table 31. Charles River Laboratories: Company Snapshot 108
Table 32. Charles River Laboratories: Business Segmentation 108
Table 33. Charles River Laboratories: Product Portfolio 109
Table 34. Charles River Laboratories: Revenue, 2016-2018, $ bn 109
Table 35. Charles River Laboratories: Recent Developments 109
Table 36. Risk Evaluation for Investing in North America Market, 2019-2030 126
Table 37. Critical Success Factors and Key Takeaways 129
Figure 1. Research Method Flow Chart 11
Figure 2. Breakdown of Primary Research 13
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 4. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 17
Figure 5. North America Pharmaceutical CDMO Market, 2019-2030, $ bn 19
Figure 6. Impact of COVID-19 on Business 23
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical CDMO Market 25
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical CDMO Market 30
Figure 9. Investment Opportunity Analysis 34
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical CDMO Market 37
Figure 11. Breakdown of North America Pharmaceutical CDMO Market by Category, 2019-2030, % of Revenue 41
Figure 12. North America Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%) 42
Figure 13. North America Pharmaceutical CDMO Market: Pharmaceutical Industry, 2019-2030, $ bn 43
Figure 14. North America Pharmaceutical CDMO Market: Biopharmaceutical Industry, 2019-2030, $ bn 44
Figure 15. Breakdown of North America Pharmaceutical CDMO Market by Service Type, 2019-2030, % of Sales Revenue 45
Figure 16. North America Addressable Market Cap in 2020-2030 by Service Type, Value ($ bn) and Share (%) 46
Figure 17. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Manufacturing Organization (CMO), 2019-2030, $ bn 47
Figure 18. North America Pharmaceutical CDMO Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn 48
Figure 19. North America Pharmaceutical CDMO Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn 49
Figure 20. North America Pharmaceutical CDMO Market: Secondary Packaging, 2019-2030, $ bn 51
Figure 21. North America Pharmaceutical CDMO Market: Pharmaceutical Contract Research Organization (CRO), 2019-2030, $ bn 52
Figure 22. North America Pharmaceutical CDMO Market: CRO for Pre-clinical Development, 2019-2030, $ bn 54
Figure 23. North America Pharmaceutical CDMO Market: CRO for Phase I Trials, 2019-2030, $ bn 55
Figure 24. North America Pharmaceutical CDMO Market: CRO for Phase II Trials, 2019-2030, $ bn 56
Figure 25. North America Pharmaceutical CDMO Market: CRO for Phase III Trials, 2019-2030, $ bn 57
Figure 26. North America Pharmaceutical CDMO Market: CRO for Phase IV Trials, 2019-2030, $ bn 58
Figure 27. North America Pharmaceutical CDMO Market: Laboratory Services, 2019-2030, $ bn 59
Figure 28. North America Pharmaceutical CDMO Market: Consulting Services, 2019-2030, $ bn 60
Figure 29. North America Pharmaceutical CDMO Market: Data Management Services, 2019-2030, $ bn 61
Figure 30. Breakdown of North America Pharmaceutical CDMO Market by Therapeutic Application, 2019-2030, % of Sales Revenue 63
Figure 31. North America Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%) 63
Figure 32. North America Pharmaceutical CDMO Market: Infectious Diseases, 2019-2030, $ bn 64
Figure 33. North America Pharmaceutical CDMO Market: Oncology, 2019-2030, $ bn 65
Figure 34. North America Pharmaceutical CDMO Market: Metabolic Disorders, 2019-2030, $ bn 66
Figure 35. North America Pharmaceutical CDMO Market: Cardiovascular Disorders, 2019-2030, $ bn 67
Figure 36. North America Pharmaceutical CDMO Market: Central Nervous System, 2019-2030, $ bn 68
Figure 37. North America Pharmaceutical CDMO Market: Pulmonary Disorders, 2019-2030, $ bn 69
Figure 38. North America Pharmaceutical CDMO Market: Gastrointestinal Disorders, 2019-2030, $ bn 70
Figure 39. North America Pharmaceutical CDMO Market: Other Therapeutic Applications, 2019-2030, $ bn 71
Figure 40. Breakdown of North America Pharmaceutical CDMO Market by End User, 2019-2030, % of Revenue 72
Figure 41. North America Addressable Market Cap in 2020-2030 by End User, Value ($ bn) and Share (%) 73
Figure 42. North America Pharmaceutical CDMO Market: Pharmaceutical & Biopharmaceutical Companies, 2019-2030, $ bn 74
Figure 43. North America Pharmaceutical CDMO Market: Medical Device Companies, 2019-2030, $ bn 75
Figure 44. North America Pharmaceutical CDMO Market: Academic Institutes, 2019-2030, $ bn 76
Figure 45. Breakdown of North America Pharmaceutical CDMO Market by Country, 2019 and 2030, % of Revenue 78
Figure 46. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%) 79
Figure 47. U.S. Pharmaceutical CDMO Market, 2019-2030, $ bn 81
Figure 48. Canada Pharmaceutical CDMO Market, 2019-2030, $ bn 84
Figure 49. Pharmaceutical CDMO Market in Mexico, 2015-2030, $ bn 86
Figure 50. Growth Stage of North America Pharmaceutical CDMO Industry over the Forecast Period 88
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
Key Players (this may not be a complete list and extra companies can be added upon request):
Company Profiles of CMO:
Aenova Group
Baxter BioPharma Solutions
Boehringer Ingelheim
Catalent Inc.
Famar S.A.
Hospira, Inc.
Jubilant Life Sciences Ltd.
Lonza Group
Patheon Inc.
Pfizer CentreSource
Recipharm AB
Vetter Pharma International GmbH
8.3.2 Company Profiles of CRO:
Charles River Laboratories
CMIC Co. Ltd
Covance Inc.
Hangzhou Tigermed Consulting Co Ltd
ICON Plc
IQVIA Holdings Inc.
LSK Global Pharma Service Co Ltd
Novotech Pty Ltd
PAREXEL International Corporation
Pharmaceutical Product Development LLC (PPD)
PRA Health Sciences Inc.
Quanticate Ltd
Samsung Bioepis Co. Ltd
SGS SA (SGS Life Sciences)
Syneos Health Inc.
WuXi AppTec Inc.
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports